Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chloride channel protein 5 (ClC-5, encoded by the CLCN5 gene) is a voltage-dependent chloride/proton exchanger predominantly expressed in the kidneys, especially within proximal tubular cells. Functionally, ClC-5 mediates the exchange of chloride ions and protons across the membrane of endosomal compartments, enabling proper acidification necessary for receptor-mediated endocytosis and the uptake of low-molecular-weight proteins and albumin. Dysfunction due to CLCN5 mutations causes Dent disease 1, an X-linked renal disorder characterized by proteinuria, renal tubular defects, nephrolithiasis, and progressive kidney failure. The protein belongs to the ClC family of ion channels, forming dimers with a unique structure enabling selective transport functions. As of now, there are no approved drugs that directly target ClC-5; patient management focuses on addressing symptoms and complications of the underlying renal disease.
Not applicable (no approved drugs directly targeting ClC-5); theoretical interventions could involve modulation of endosomal acidification or chloride ion transport.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chloride channel protein 5 (ClC-5).